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Selective depletion of macrophages  
reveals distinct, opposing roles  
during liver injury and repair
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Macrophages perform both injury-inducing and repair-promoting tasks in different models of inflammation, 
leading to a model of macrophage function in which distinct patterns of activation have been proposed. We 
investigated macrophage function mechanistically in a reversible model of liver injury in which the injury and 
recovery phases are distinct. Carbon tetrachloride–induced liver fibrosis revealed scar-associated macrophages 
that persisted throughout recovery. A transgenic mouse (CD11b-DTR) was generated in which macrophages 
could be selectively depleted. Macrophage depletion when liver fibrosis was advanced resulted in reduced 
scarring and fewer myofibroblasts. Macrophage depletion during recovery, by contrast, led to a failure of 
matrix degradation. These data provide the first clear evidence that functionally distinct subpopulations of 
macrophages exist in the same tissue and that these macrophages play critical roles in both the injury and 
recovery phases of inflammatory scarring.
Introduction
Macrophages feature prominently at diverse sites of inflammation 
and have been linked to the process of inflammation and repair, 
demonstrating a repertoire of activities that include regulating 
inflammatory cells, tissue debridement, cell killing, recruiting and 
activating myofibroblasts, and regulating spontaneous recovery 
of fibrosis in physiological or aberrant wound healing (1–6). In 
response to injury, cells of mesenchymal origin transdifferentiate 
into myofibroblasts, migrate, and generate the matrix components 
of scar tissue (7, 8). Myofibroblasts also have the capacity to express 
MMPs and tissue inhibitors of metalloproteinase (TIMPs), through 
which they regulate degradation of matrix components (9). The pre-
cise role of macrophages at the site of injury is unclear (10, 11), but 
they are known from in vitro experiments to generate a diverse array 
of agents that regulate the degradation of matrix (7, 10, 12, 13).
Recent cell surface phenotyping studies suggest that distinct 
macrophage populations exist. For example, the hemoglobin 
scavenger receptor CD163 is expressed by a subpopulation of 
macrophages at inflamed sites (14). Likewise, pattern recogni-
tion receptors such as dectin-1 and mannose receptors are high-
ly expressed only in subsets of macrophages in inflamed tissue 
(15). To make sense of this diversity, 2 forms of inflammatory 
macrophages have been proposed: the classically activated macro-
phage and the alternatively activated macrophage (aa-M) (11). The 
former, activated by TH1 lymphokines, bacterial and fungal cell wall 
components, or degraded matrix (e.g., hyaluronic acid), liberates 
proinflammatory cytokines and chemokines and is predominantly 
lytic to matrix components (16, 17). The aa-M is activated by TH2 
lymphokines, including interleukin-4, as well as apoptotic cells 
and corticosteroids, and produces anti-inflammatory cytokines 
including interleukin-10 and TGF-β. When cultured with myo-
fibroblasts, aa-Ms promote complex matrix deposition (11, 13, 
18–20). However, these phenotypes have been defined predomi-
nantly in tissue culture models and may not reflect the complexity 
of macrophage function in vivo. In an injured tissue, macrophages 
appear to display features of both the proinflammatory and alter-
native activation programs (18, 20–23).
We set out to define the role of macrophages in a well-described 
and defined model of liver injury induced by carbon tetrachloride 
(CCl4) in rodents in which inflammation and fibrosis occur. With 
iterative injury (3 months in mice, 1 month in rats), extensive scar-
ring develops as indicated by transdifferentiation of hepatic stel-
late cells (HSCs) into myofibroblasts (known as activated HSCs), 
intense myofibroblast proliferation, and progressive laying down 
of complex polymeric matrix components (7). Following cessation 
of CCl4 injections, the scarring resolves completely (7). These dis-
tinct phases of injury, repair, and resolution make this an ideal 
model for studying injury- and repair-associated macrophages.
Here we show, using conditional macrophage depletion, that scar-
associated macrophages (SAMs) are essential for normal injury and 
recovery responses. Macrophage depletion in mice during injury 
was associated with a dramatic loss of myofibroblast-like HSCs and 
resulted in extensive loss of matrix components. Depletion during 
the recovery phase, however, attenuated matrix degradation, partic-
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ularly perisinusoidal fibrosis. These data define 2 distinct activities 
of macrophages with opposite but complementary functions.
Results
Macrophages are associated with liver fibrosis during injury and repair. In 
order to determine the role of macrophages in liver injury and repair, 
we induced fibrosis (4 weeks of CCl4), cirrhosis (12 weeks of CCl4), 
and spontaneous recovery following both fibrosis and cirrhosis in 
rats as previously described (7, 24). Liver sections were stained for 
markers of collagen, macrophages, and activated HSCs (Figure 1). 
At all stages of progressive fibrosis and cirrhosis, SAMs were found 
in significant numbers. SAMs were found within and apposed to the 
bands. In particular, the perisinusoidal fibrosis was rich in SAMs (Fig-
ure 1B). SAMs were also found to be associated with resolving areas 
of fibrosis in spontaneous recovery in both the fibrotic and cirrhotic 
models. Whereas over 28 days of spontaneous recovery, fibrosis com-
pletely resolved after 4 weeks of CCl4 intoxication, in spontaneous 
recovery from 12 weeks of cirrhosis, the perisinusoidal fibrosis had 
completely resolved, but the residual linking fibrotic septa persisted 
and continued to be associated with SAMs (Figure 1, B and C).
To evaluate the relationship and dynamics of the populations of 
myofibroblast-like activated HSCs and macrophages during spon-
taneous resolution of fibrosis, we stained sections at time points 
during spontaneous recovery from 4 weeks of fibrosis and counted 
both HSCs that stained positive for α-SMA and SAMs that stained 
positive for ED-1 (8) (Figure 1C). A very close relationship between 
the 2 populations of cells was noted. During the first 7 days of 
recovery, 89% ± 6% of HSCs disappeared, whereas 60% ± 5% of 
SAMs disappeared. The close correlation between the numbers of 
SAMs and HSCs suggests an interdependence.
A model for selective depletion of macrophages. To generate a system 
in which macrophage function could be studied in vivo, we took 
advantage of a conditional ablation system mediated by diphthe-
ria toxin (DT) receptor (25, 26). This system relies on the fact that 
the mouse DT receptor (heparin-binding EGF; hbEGF) binds DT 
poorly compared with the human and simian molecules (27). Thus, 
transgenic expression of the human DT receptor (DTR) confers 
sensitivity to DT and permits ablation in vivo when DT is injected.
Six transgenic mouse lines were generated using the CD11b-DTR 
construct (Figure 2A) that uses the CD11b gene regulatory ele-
ments (28) for macrophage-specific expression of a DTR molecule 
fused with GFP. Using an RT-PCR assay, we showed that transgen-
ic mouse–derived BM macrophages (6) expressed the macrophage-
specific gene F4/80 as expected (Figure 2B). Two out of 6 trans-
genic lines also showed expression of the transgene, with line 34 
showing the highest level (see Figure 2C for positive and negative 
examples). As a result, line 34 was expanded for further investiga-
tion and is referred to hereafter as CD11b-DTR. As a test of ablation 
specificity, we performed i.p. injections of DT and examined, using 
FACS analysis, the effects on CD3+ T cells in the spleen and peri-
toneal cavity and B220+ B cells in the spleen (Figure 2, D–G). DT 
was administered in 2 doses at 48-hour intervals at 25 ng/g body 
weight and cell number assessed 24 hours later. Unlike previous 
DTR ablation models (25), the CD11b construct gave insufficient 
GFP signal for FACS analysis.
As expected, the F4/80-positive peritoneal population was unaf-
fected in wild-type mice receiving 2 doses of DT (Figure 2D) but 
was eliminated in CD11b-DTR mice (Figure 2E). Importantly, in 
CD11b-DTR mice with complete peritoneal macrophage elimina-
tion, the CD3+ peritoneal cavity T cells were unaffected (Figure 2E). 
The relative increase in CD3+ and double-negative cells in the DT-
treated CD11b-DTR mice is due to the plotting of equal numbers of 
events. B220+ and CD3+ populations in the spleen were unaffected 
in either wild-type (Figure 2F) or CD11b-DTR mice (Figure 2G).
Because the endogenous CD11b gene is expressed in both 
macrophages and granulocytes, we determined which of the cell 
Figure 1
The relationship between SAMs, collagenous bands, and HSCs during CCl4 injury and recovery in the Sprague-Dawley rat. (A) Sirius red stain-
ing (magnification, ×100) of liver for collagenous bands at 4, 6, and 12 weeks of disease, and following 28 days of recovery after 12 weeks of 
injury. (B) ED-1 macrophages (magnification, ×100) are associated with scar tissue after 4, 6, and 12 weeks of disease, and following 28 days 
of recovery after 12 weeks of injury. (C) Graph of SAMs and α-SMA–positive HSCs at different stages of recovery from CCl4-induced fibrosis (4 
weeks intoxication). Note the rapid decline in HSCs in the early phase of recovery. 
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types recruited to the peritoneal cavity by injections of sterile Brew-
er’s thioglycollate (BTG) could be killed by subsequent injections 
of DT. In CD11b-DTR homozygotes, BTG was injected 6 hours 
prior to injection of DT at 25 ng/g mouse weight and cells harvest-
ed for analysis 24 hours later. A morphological analysis showed 
that cells of monocyte/macrophage, eosinophil, neutrophil, baso-
phil, and lymphocyte morphology were present in control mice 
(Figure 2H and Table 1) and that cells of monocyte/macrophage 
morphology only were greatly reduced in those treated with DT 
(Figure 2I and Table 1). It was particularly striking that most BTG-
elicited, DT-treated peritoneal cells were neutrophils (Figure 2I). 
Importantly, this showed that granulocytes were not sensitive to 
DT. Furthermore, blood leukocytes from DTR mice 24 hours fol-
lowing a single i.v. injection of DT revealed a selective depletion of 
F4/80-positive monocytes from 6.5% ± 3.3% to 1.5% ± 1.3%.
DT effectively depletes SAMs. A model of CCl4-mediated liver 
fibrosis similar to that used in the rats was induced in CD11b-
DTR mice. At 11 weeks of CCl4 intoxication, the disease group of 
mice received 2 further doses of CCl4 and 3 macrophage-deplet-
ing doses of DT (or PBS as control) over the 12th week. Livers 
were harvested at the end of 12 weeks and assessed for SAMs. 
At peak fibrosis (12 weeks), control livers (treated with PBS 
and CCl4) exhibited extensive macrophage infiltration in and 
surrounding the scar (Figure 3, A and E), which was markedly 
attenuated in both the treatment groups (DT and CCl4) (Figure 
3, B and E). We went on to establish a model to determine the 
phenotype of livers in which macrophages were depleted at the 
onset of spontaneous resolution. After 12 weeks of CCl4-medi-
ated injury, another cohort of mice was allowed to recover spon-
taneously for 1 week. Forty-eight hours following the final injec-
tion of CCl4, mice received DT (or control PBS) for 5 days, and 
then livers were assessed for SAMs. This period of recovery covers 
the first 7 days when most of the loss of scar was seen in our 
previous rat and mouse recovery models. In the control-treated 
recovery group, SAMs could be seen by F4/80 staining (Figure 3, 
C and F). The total number of SAMs had declined markedly after 
7 days of recovery (3.2% ± 1.7% area) compared with peak fibrosis 
(18% ± 3.8% area) in control mice. However, administration of 
DT by either route during recovery led to an approximately 50% 
reduction in SAMs at 7 days of recovery (Figure 3F). Our sample 
time in recovery was determined to maximize potential differ-
ences in matrix degradation and scar resolution. This necessar-
ily meant harvest at a time point when most of the SAMs were 
lost from control livers. Consequently, a significant difference 
in overall SAM number was not seen in DT-treated relative to 
control mice at this time point.
Table 1
The effect of DT on peritoneal cell subtypes elicited with BTG
TreatmentA Monocytes/ Polymorphs Lymphocytes Mast cells
 macrophage Basophils Eosinophils Neutrophils  
BTG/DTmut 33 ± 1.9 (54%) 1.1 ± 0.5 (1.8%) 2.6 ± 0.4 (4.3%) 21 ± 2.7 (35%) 1.8 ± 0.5 (3.0%) 1.0 ± 0.8 (2.0%)
BTG/DT 8.1 ± 0.9 (14%) 2.0 ± 0.7 (3.4%) 1.5 ± 0.2 (2.5%) 44 ± 3.7 (75%) 2.3 ± 0.4 (3.9%) 0.9 ± 0.3 (1.5%)
AA single i.p. injection of DT at 25 ng/g mouse weight 6 hours after i.p. injection of 4 ml of 4% BTG in PBS.
Figure 2
Structure of the CD11b-DTR transgene and ablation specificity. (A) Dia-
gram representing the MacT6 construct. The cDNA for the DTR-eGFP 
fusion gene is inserted between the human CD11b promoter (coordi-
nates –1,704 to +83 relative to transcription start) and human growth 
hormone (hGH) sequence that provides splicing and polyadenylation 
sequences. Small half-arrows indicate location of the nucleotide pair 
used for RT-PCR transcript detection; right-facing arrow, transcription 
start point; gray boxes, exons; and open boxes, untranslated regions. 
RT-PCR analysis performed on BM-derived macrophages for the con-
trol F4/80 (B) and transgenic DTR-eGFP (C) transcripts. Results shown 
for WT mice and CD11b-DTR lines 34 (positive-line example) and 35 
(negative-line example). The eGFP-hGH oligonucleotide pair specifi-
cally amplified the transgene mRNA; amplification products were not 
evident in samples from WT mice or when reverse transcriptase (RT) 
was omitted. (D–G) FACS assessment of peritoneal and spleen popu-
lations. (D) In WT mice, injection of 2 doses of DT at 25 ng/g mouse 
weight does not affect either the small population of CD3+ T cells (upper 
left quadrant) or the larger population of F4/80+ macrophages (lower 
right quadrant) in the peritoneal cavity. (E) In heterozygous CD11b-
DTR mice receiving DT, the F4/80+ population is eliminated while the 
CD3+ cells remain. Neither the CD3+ nor the B220+ cells in the spleen 
were affected by DT injection either in WT (F) or CD11b-DTR mice 
(G). Wright-Geimsa–stained cytospin preparations of BTG-elicited peri-
toneal cells after DTmut (H) or DT (I) injection into CD11b-DTR mice. 
Normal proportions of elicited peritoneal cells were observed with injec-
tion of DTmut, but the absence of macrophages and preponderance of 
neutrophils was apparent in mice treated with DT.
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SAMs promote matrix deposition and support HSCs during injury. Livers 
depleted of SAMs during CCl4 injury were assessed for matrix com-
ponents. Picrosirius red staining highlights polymeric and mono-
meric collagen matrix (29). Liver sections were assessed for the area 
of sirius red (Figure 4, A and E). Macrophage depletion markedly 
reduced sirius red. Sections were stained for collagen III, a represen-
tative fibrillar collagen secreted in excess in liver fibrosis (Figure 4, 
C and G). Macrophage depletion also resulted in substantial reduc-
tion in the amount of this abnormal collagen. Another component 
of mature scar tissue that may promote matrix cross-linking is elas-
tin (30). Depletion of macrophages leads to marked reduction of 
elastin at 12 weeks compared with that in controls (Figure 4, D and 
H). Thus, each representative component of the scar matrix exam-
ined was substantially reduced during progressive liver injury in 
the absence of SAMs, indicating that SAMs either directly or indi-
rectly promote the expression of matrix proteins and/or regulate 
the maintenance of abnormal extracellular matrix.
Because the collagens and elastin are produced primarily by 
myofibroblast HSCs (9, 31), we wondered whether the profound 
effect of SAMs on the pattern of fibrosis was via regulation of the 
HSC population. The number of α-SMA–positive cells in the scars 
was assessed (Figure 4, B and F). Macrophage depletion by admin-
istration of DT either i.p. or i.v. led to a marked reduction in the 
number of HSCs. This indicates 
that SAMs support the activated 
HSC (myofibroblast) population, 
and, at least in part via this mecha-
nism, promote fibrosis. We have 
previously determined that the 
population of HSCs is determined 
by the balance of proliferation and 
apoptosis (32). Therefore, BrdU 
uptake in scar cells was assessed 
in all livers (Table 2). During SAM 
depletion, the number of prolifer-
ating scar-associated cells was markedly reduced, suggesting that 
SAMs directly induce HSC proliferation. The number of scar-asso-
ciated apoptotic cells was also decreased following depletion of 
SAMs (Table 2). Therefore, SAMs may regulate both proliferation 
and apoptosis of myofibroblast HSCs.
SAMs promote the resolution of fibrosis during recovery. Livers 
depleted of SAMs during recovery were assessed for matrix com-
ponents. Sirius red material decreased by 85% in control (PBS-
treated) mice after recovery compared with control mice at peak 
fibrosis (PBS and CCl4) (Figure 5, A and E). However, those mice 
with depletion of SAMs induced by i.p. or i.v. administration 
of DT during recovery had persistence of sirius red material, 
increasing from 1% of the biopsy to more than 3% of the biopsy. 
While the overall thickness of the bands of fibrosis had reduced 
during recovery in spite of SAM depletion, the most prominent 
feature was a persistence of perisinusoidal fibrosis in the absence 
of SAMs (Figure 5C). The amount of perisinusoidal fibrosis was 
assessed using an established scoring system (33) and was found 
to persist at a comparable level to peak fibrosis in the tissue from 
recovering livers as a result of depletion of SAMs (Table 2). The 
increase in perisinusoidal fibrosis score from 1.0 to 1.9 as a result 
of SAM depletion compares with a score of 2.5 at peak fibrosis in 
the control diseased mice. Thus, there is very little attenuation 
of perisinusoidal fibrosis in the absence of SAMs. Therefore, in 
stark contrast to the function of SAMs during CCl4 injury, SAMs 
during recovery promote degradation and resorption of matrix 
components. To be sure that this resorption included complex 
scar-associated matrix proteins, both collagen III (Figure 5, C 
and G) and elastin (Figure 5, D and H) were assessed. There was 
50% more collagen III in livers from mice depleted of SAMs dur-
ing recovery (predominantly due to a failure to resorb the peri-
sinusoidal fibrosis). Elastin, a durable component of scar tissue, 
declined in response to recovery. However, following depletion of 
SAMs, there was no evidence of a reduction in elastin content.
Figure 3
The effect of DT treatment on SAMs in CD11b-DTR mouse liver at 
peak fibrosis and after 7 days of spontaneous recovery. (A–D) Pho-
tomicrographs (magnification, ×400) showing (A) macrophages (Mφ) 
associated with areas of scarring after 12 weeks of CCl4-induced injury; 
(B) absence of macrophages in an area of scarring at 12 weeks of CCl4 
injury, following 5 days of macrophage depletion; (C) macrophages 
associated with resolving fibrotic band, at 7 days of recovery from CCl4 
injury; and (D) absence of macrophages in scar following macrophage 
depletion during spontaneous recovery. (E and F) Area of macrophage 
in fibrotic bands (E) at peak fibrosis following treatment with i.v. PBS, 
i.p. DT or i.v. DT, or (F) after 7 days of spontaneous recovery after 
treatment with i.v. PBS, i.p. DT, or i.v. DT (**P < 0.01).
Table 2
The effect of macrophage depletion on proliferation, apoptosis, and perisinusoidal fibrosis
 Injury Recovery
  Control i.p. DT i.v. DT Control i.p. DT i.v. DT
Scar-associated cells per 50 hpf
 BrdU+ 142 ± 47A 47 ± 5 57 ± 3 8.8 ± 6.7 16.7 ± 3.1 9.7 ± 2.9
 TUNEL+ 43 ± 17A 9 ± 3 12 ± 5 3.4 ± 2.3 4.5 ± 2.5 3.7 ± 2.5
Perisinusoidal fibrosis score 2.5 ± 0.9   1.0 ± 1.2B 1.8 ± 0.8 1.9 ± 0.7
AMean ± SEM; P < 0.01 by ANOVA. BMean ± 95% confidence interval; P < 0.05 by Wilcoxon rank sum test. 
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Thus, SAMs during recovery mediate opposite effects on matrix 
components and fibrosis compared with SAMs during injury. Both 
macrophages and activated HSCs can liberate a range of matrix-
degrading MMP enzymes and regulate their activity via expression 
of TIMPs. Moreover, matrix degradation in spontaneous recov-
ery from fibrosis is associated with a loss of activated HSCs (33), 
which are known to be quantitatively the major source of matrix 
(9). We therefore set out to determine whether the persistence of 
scar matrix during recovery in macrophage-depleted mice was due 
to persistence of myofibroblast-like activated HSCs. The area of 
α-SMA cells during recovery was assessed in the presence of SAMs 
or following SAM depletion. Although there was a trend toward 
persistence of α-SMA cells (Figure 5, B and F), this was not signifi-
cant. Furthermore, when proliferation and apoptosis were assessed 
in the scars, no clear difference was seen (Table 2).
SAMs derive from both circulating monocytes and resident cells of the 
liver. In the liver there are 2 potential sources of SAMs. One derives 
from the circulating pool of BM-derived monocytes, and the other 
from the population of resident liver macrophages, the Kupffer 
cells. Because we had determined that 2 functional subsets of 
macrophages exist in liver injury, it was important to determine 
what role the Kupffer cells played in the disease process. To date, 
no phenotypic marker has been described that distinguishes 
Kupffer cells from monocyte-derived macrophages. We therefore 
took advantage of the observation that Kupffer cells in healthy 
livers of mice chimeric for BM cells are not replaced by BM-
derived cells after 8 weeks of chimerism (data not shown). Thus, 
the population of Kupffer cells can be distinguished from mono-
cyte macrophages in BM chimeric mice. In female mice with male 
BM, SAMs in livers following 12 weeks of liver injury were assessed 
for the presence of the Y chromosome using established scoring 
methods (Figure 6) (34). In 5-μm tissue sections, 28.3% ± 4.2% 
of SAMs contained the Y chromosome, indicating that 45.7% ± 6.8% 
of SAMs were derived from the BM-derived monocyte pool (see 
Methods for details). These data indicate that 2 populations of 
macrophages exist: 1 derived from monocytes, the other derived 
from a nonhematogenous source. It is likely that the second popu-
lation derives from resident Kupffer macrophages.
SAMs during disease are phenotypically distinct from macrophages dur-
ing recovery. We have demonstrated that SAMs during disease are 
Figure 4
Components of the fibrotic response at peak fibrosis following CCl4 injury in the CD11b-DTR mouse, from control and macrophage-depleted 
animals. (A) Sirius red staining (magnification, ×200) at 12 weeks after CCl4 injury with no depletion or macrophage depletion. Note extensive 
perisinusoidal fibrosis that is lost with macrophage depletion. (B) Extensive α-SMA–positive HSCs (magnification, ×200) in the fibrotic bands 
are seen with no depletion but not following macrophage depletion. (C) Collagen III staining (magnification, ×100) showing both fibrotic bands 
and perisinusoidal fibrosis with no depletion and following depletion. (D) Elastin staining (magnification, ×200) with no depletion or macrophage 
depletion. Macrophage depletion during CCl4 injury results in (E) a reduction of sirius red staining and (F) a reduction of area of α-SMA–positive 
HSCs. (G) Collagen III and (H) elastin are reduced in fibrotic matrix following macrophage depletion (*P < 0.05, ** P < 0.01).
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functionally distinct from SAMs during recovery. It was important 
to determine whether a phenotypic marker could be elucidated. 
Analysis of tissue sections stained with macrophage markers 
CD11b, CD68 (data not shown), and F4/80 (Figure 3) unveiled no 
differences in macrophage expression during disease and recovery. 
In vitro studies of BM macrophages have shown that macrophages 
can be polarized into distinct cell types that are distinguished by 
expression of TNF-α, IL-10, and TGF-β1 (11). We used a quantita-
tive RT-PCR method to determine the amounts of tnfα and il-10 
transcripts during injury and repair (Table 3). Previous studies 
have shown that RNA levels correlate closely with protein levels 
for these cytokines (35). During injury, tnfα transcript was 14-fold 
more abundant than during recovery (Table 3). During injury, il-10 
transcript was also expressed more abundantly than during recov-
ery, though the differences were less marked. Furthermore, tnfα 
transcript was 360-fold more abundant than il-10. These data sug-
gest that SAMs during injury express high levels of TNF-α and lit-
tle IL-10, but that SAMs during recovery express little TNF-α and 
little IL-10. Although total tgfβ1 transcript was not significantly 
altered between disease and recovery (Table 3), tgfβ1 transcript 
levels have been shown not to correlate well with protein prod-
uct (36), and TGF-β1 expression is not limited to macrophages 
or immune cells. Liver sections were therefore immunolabeled for 
TGF-β1 expression using a well-validated antibody (37). In scars of 
active disease we found abundant expression of TGF-β1 in cells of 
the scar (morphologically the source cells were inflammatory cells 
and activated HSCs/myofibroblasts), extracellular matrix, and 
cells with the morphology of hepatocytes immediately adjacent 
to the scars (Figure 7A). Sections labeled with control rabbit IgG 
revealed no specific binding (data not shown). In contrast TGF-β1 
was absent from the scars during recovery (Figure 7B). When SAMs 
were depleted during injury, the scars also did not express TGF-β1, 
Table 3
Relative expression of cytokine transcripts in whole liver during 
disease and recovery
 Disease Recovery
tnfα 1.82 ± 0.54 0.13 ± 0.05
il-10 0.005 ± 0.001 0.002 ± 0.0002
tgfβ1 0.33 ± 0.16 1.04 ± 0.4
Expression is relative to GAPDH. n = 4 per group. Data are expressed 
as mean ± SEM.
Figure 5
Components of the resolving fibrosis after 7 days of spontaneous recovery from CCl4-induced injury in control and macrophage-depleted CD11b-DTR 
mice. (A) Sirius red–positive material (magnification, ×100) following 7 days of recovery with no depletion or macrophage depletion. Note extensive 
loss of fibrotic bands and perisinusoidal fibrosis. (B) α-SMA–positive HSCs (magnification, ×200) in the liver after 7 days of recovery with no depletion 
or macrophage depletion. (C) Collagen III staining (magnification, ×100) following 7 days of recovery with no depletion or macrophage depletion. Note 
persistence of perisinusoidal fibrosis (arrowheads). (D) Elastin staining (magnification, ×200) with no depletion or macrophage depletion. Macrophage 
depletion during recovery results in (E) persistence of the total area of fibrosis detected by sirius red staining but (F) nonsignificant persistence of 
α-SMA–positive HSCs. Depletion of macrophage during recovery results in persistence of (G) excess collagen III and (H) elastin (*P < 0.05).
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though expression could still be seen in cells with the morphology 
of hepatocytes (data not shown). Furthermore, when SAMs were 
depleted during recovery, TGF-β1 expression was still not seen in 
scars. Taken together, these observations indicate that SAMs dur-
ing injury not only express TGF-β1, but also likely induce expres-
sion in other cells of the scar, including HSCs, whereas the SAMs 
present after the onset of recovery do not express this cytokine.
Discussion
To assess macrophage function at distinct phases of disease and 
recovery, we developed a novel system for depletion of macrophages 
during disease. The role of the inflammatory tissue macrophage has 
remained a subject of debate, at least in part because macrophages 
are associated with both tissue injury and repair (10). In addition, 
when macrophages have been depleted in a series of injury models, 
the results have been conflicting (38, 39). Macrophage have been 
successfully depleted during induction of several animal models of 
inflammatory diseases by antimacrophage serum or by administra-
tion of liposomal clodronate (1, 3, 4, 10, 40). While both undoubted-
ly deplete macrophages, the former has pleiotropic effects, and the 
latter has been complicated by neutrophil depletion, toxicity, and 
ineffective depletion in some tissues (40, 41). To circumvent these 
difficulties, we developed a novel transgenic mouse in which minute 
injections of DT can deplete macrophages. This is possible because 
the mouse equivalent of the DT receptor (hbEGF) binds DT very 
poorly; mice are therefore insensitive to DT (27) while tissue-specific 
expression of the human DT receptor confers sensitivity (25, 26).
We have now shown that the deletion of the macrophage popu-
lation either during injury or during repair and resolution has dra-
matically different effects on the overall fibrotic response. Specifi-
cally, in progressive inflammatory injury, macrophage depletion 
results in amelioration of fibrosis. By contrast, depletion during 
recovery results in a failure of resolution with persistence of cel-
lular and matrix components of the fibrotic response. These data 
represent the first definitive demonstration that macrophages play 
distinct roles in injury and repair and highlight the critical obser-
vation that a given cell may be both pathogenic and beneficial.
Our experiments suggest that over a period of a few days, 2 func-
tionally distinct types of macrophages exist in the injured liver. 
During the injury phase (a time when chemokines, complement 
components, and proinflammatory cytokines are abundant) inju-
ry-associated macrophages promote myofibroblast proliferation 
and apoptosis. On balance, macrophages have the effect of increas-
ing myofibroblast numbers. As a result, fibrogenesis predominates 
and matrix is deposited. The phenotype of macrophages associ-
ated with the injury phase is closest to that of the aa-Ms described 
by others (11). However, it is present in response to injury normally 
associated with classically activated macrophages, as it is present 
at a stage when proinflammatory cytokines are released.
In contrast, during recovery from injury, a population of 
macrophages predominates that does not support HSC survival 
and promotes matrix degradation and, in that regard, resembles 
classically activated macrophages. This macrophage population, 
however, is present during resolution of injury and at a time when 
proinflammatory mediator levels are decreasing, an observation 
reinforced by our studies of TNF-α in this model. Moreover, these 
2 functional phenotypes are separated chronologically in the liver 
by only a few days, suggesting that they may represent a single pop-
ulation. Therefore, we suggest that the yin and yang of the classi-
cally activated macrophage/aa-M model is inadequate to reflect 
the complex roles of these cells in vivo during liver injury.
In our study, the SAMs during injury are associated with 
high expression of TGF-β1 in the scars and high levels of liver 
tnfα transcript. In contrast, during recovery, SAMs are not 
associated with TGF-β1 generation in the scars, and the liver 
tnfα transcript is attenuated. We have identified 2 sources of 
SAMs. One is monocyte-derived, and the other is derived from 
a nonhematogenous source. It is likely that this other source of 
SAMs is the resident liver macrophages, the Kupffer cells. It is 
tempting to speculate as to whether one functional population 
of macrophages derives from monocytes and the other from 
Kupffer cells. Further experiments (beyond the scope of the cur-
rent study) will be required to determine whether the functional 
distinctions are clearly related to macrophage origin.
Our study indicates that SAMs during disease are associated with 
high levels of proliferation and apoptosis in the scars, but that these 
Figure 6
Y chromosome–positive SAMs after 12 weeks of liver injury in female 
BALB/c mice chimeric for male BM (magnification, ×600). F4/80-labeled 
macrophages (red) are located in the region of a scar. Y chromosome–
FITC hybridization (green) can be seen in nuclei labeled with DAPI (blue). 
Note macrophages with nuclei containing Y-chromosomal DNA (arrow-
heads) and also macrophages without Y-chromosomal DNA (arrows).
Figure 7
TGF-β expression in the fibrotic bands (magnification, ×400). (A) After 
12 weeks of disease in the mouse model, fibrotic bands (denoted by 
arrowheads) contain numerous cells showing immunofluorescence 
for TGF-β. In addition, cells with the morphology of hepatocytes also 
express cytoplasmic TGF-β (arrow). (B) Following 7 days of recovery 
from injury, the fibrotic bands show no evidence of TGF-β expression. 
In addition, no hepatocytes show TGF-β expression.
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parameters are markedly decreased by depletion of SAMs. Thus, the 
SAMs may induce both proliferation and apoptosis and, as such, 
maintain a population of HSC myofibroblasts. Macrophages are 
known to induce cell cycle–dependent cell death in some settings 
(42), and so there is reason to consider this mechanism of cell num-
ber regulation in the injured liver. Furthermore, macrophages can 
liberate both potent myofibroblast growth factors, such as PDGF, 
and proapoptotic factors, such as TNF-α. Indeed, SAMs during dis-
ease generate TNF-α. Our data reveal that after 7 days of recovery, 
apoptosis and proliferation in the scars is reduced and the popula-
tion of HSC myofibroblasts is much reduced. Thus, SAMs during 
recovery do not share these characteristics with SAMs during dis-
ease. In a previous study, we have shown that the loss of HSCs dur-
ing recovery in rats is due to a wave of apoptosis occurring predom-
inantly in the first 3 days (7). We do not see this wave of apoptosis 
in the current study, in which we focused on 7 days of recovery in 
order to demonstrate changes in matrix components. It is likely 
that the wave of apoptosis occurred at an earlier time point.
Previous studies using other methods to modify or deplete 
macrophages have pointed to a role for macrophages in mediating 
the fibrotic response (4, 39). Those studies have been inconsistent, 
however, which may reflect nonspecific depletion of other cell types 
or the existence of distinct functional populations of macrophages in 
the different models of inflammation and scarring that were studied. 
Our new conditional ablation system is nontoxic, is cell type–specific, 
is effective in many tissues, and offers the possibility of time point–
selective deletion of cells during a range of inflammatory processes.
We suggest that our description of the roles of macrophages in 
functional terms should provide the basis for a series of future 
functional studies in vivo to define more accurately the nature, 
specific attributes, and dynamics of the macrophage population(s) 
present in inflammation and repair. We further suggest that a 
description of macrophage populations based on functional stud-
ies in vivo should form the basis of a rational and clinically rel-
evant classification of the cell.
Methods
Materials
All reagents were from Sigma-Aldrich unless stated otherwise. DT and 
mutant DT (DTmut), which lacks intracellular enzyme activity, were from 
List Biological Laboratories Inc. Animals were housed in a standard sterile 
animal facility with free access to chow and water. All manipulations and 
procedures were undertaken with approved license from the Animal Scien-
tific Procedures Division of the Home Office (London, UK).
Transgenic construct
The CD11b promoter from coordinates –1,704 to +83 (28) was used to drive 
expression of the human hbEGF cDNA(27). Splicing and polyadenylation 
signals were provided by a region of the human growth hormone gene 
that had previously worked effectively with the CD11b promoter (28). The 
fusion protein between hbEGF and GFP was generated by continuing the 
open reading frame of hbEGF at the final residue with the open reading 
frame of GFP at residue 1. The transgene fragment was excised using the 
HindIII and NotI restriction endonucleases and purified using standard 
techniques. The CD11b-DTR construct was used to generate transgenic mice 
(43) using conventional techniques (44). Transgene expression was detected 
using an RT-PCR assay. The primer sequences used were AAGATCCGCCA-
CAACATCG for the 5′ primer and GCAGCTCTAGGTTGGATTTCTG for 
the 3′ primer. No PCR product could be amplified from genomic DNA.
FACS analysis
Mouse peritoneal and spleen cells were isolated using conventional meth-
ods (35). Blood leukocytes were purified from heparinized blood by cen-
trifugation followed by aspiration of buffy coat. The latter was washed 3 
times in PBS to remove platelets. Remaining erythrocytes were removed 
by hypotonic lysis on ice, followed by further PBS washes. A total of 
2 × 106 cells were preincubated with FACS buffer containing Fc Block 
(BD Biosciences — Pharmingen). Fifty microliters of FACS buffer con-
taining FITC- or PE-conjugated anti-B220, anti-CD3 (BD Biosciences 
— Pharmingen), or anti-F4/80 (Serotec) was then added and incubated at 
4°C for 1 hour. Cells were washed 3 times in FACS buffer and fixed in 2% 
formaldehyde in PBS prior to analysis.
Disease models
Progressive fibrosis demonstrating complete spontaneous recovery. CCl4 liver fibro-
sis was induced in Sprague-Dawley rats by twice weekly i.p. injections of 
CCl4 in sterile olive oil (7). After 4 weeks, cohorts of animals were allowed 
to spontaneously recover for periods of up to 28 days (7).
Advanced fibrosis and micronodular cirrhosis. CCl4 liver fibrosis was 
induced and analyzed after 6 weeks (fibrosis) and 12 weeks (advanced 
micronodular cirrhosis). Cohorts were allowed to recover for 28 days (9, 
24). The more advanced cirrhosis demonstrated a reduced capacity for 
spontaneous resolution. Nevertheless, there was considerable remodel-
ing during the recovery period.
Mouse model of hepatic fibrosis and spontaneous recovery from fibrosis in DTR mice. 
Twenty-four adult DTR mice (FVB/N) were injected with 0.25 μl/g of CCl4 i.p. 
twice weekly for 12 weeks. During the 12th week, half the mice (disease group) 
were given either (a) DT (10 ng/g i.v. by tail vein) immediately following the 
first injection of CCl4 that week, DT (i.v.) 24 hours later, and DT (i.v.) a further 
48 hours later to coincide with the next injection of CCl4; (b) DT (25 ng/g i.p.) 
over a similar schedule; or (c) 100 μl PBS (i.v.) as control to coincide with the 
DT injections. During the 13th week, the remaining mice (recovery group) 
did not receive any further CCl4 injections. However, 72 hours following the 
final CCl4 injection, mice were given either (a) DT (10 ng/g i.v.), DT (i.v.) 24 
hours later, and DT (i.v.) a further 48 hours later; (b) DT (25 ng/g i.p.) over 
a similar schedule; or (c) 100 μl PBS (i.v.) to coincide with the DT injections. 
Livers were harvested 24 hours following the final dose of DT or PBS.
Mouse BM transplant model to trace the lineage of the SAMs
In order to trace the lineage of the SAMs, we performed sex-mismatched 
BM transplants from male donor mice into female recipients, which allowed 
us to detect male BM-derived SAMs through in situ hybridization for the Y 
chromosome combined with immunostaining for F4/80 antigen. Six-week-
old female recipient BALB/c mice (n = 7) underwent whole-body, lethal γ irra-
diation (8 Gray) in divided doses. This was followed by a tail vein injection 
with whole BM from 3 male BALB/c donors. Femurs from the male donors 
were removed and marrow was flushed with PBS using a needle syringe. The 
product was filtered twice through a 70-micron tube filter and centrifuged to 
purify the cells. One million BM cells were resuspended in 200 μl of PBS and 
injected i.v. into each recipient female on the same day. Four weeks later, liver 
fibrosis was induced by repeated CCl4 injection for 12 weeks as described 
above, and tissue was collected 72 hours following the last CCl4 injection.
Immunostaining
Rat SAMs were detected in 3-μm paraffin-embedded sections using ED-1 
antibody (Serotec) as previously described (45). α-SMA was detected by incu-
bation with 1A4 antibody (DAKO) as previously described (7). Mouse SAMs 
were detected in 3-μm methyl Carnoys–fixed paraffin-embedded sections 
using anti-F4/80 antibody (46), except for the tissue analysis requiring in situ 
hybridization, where 5-μm formalin-fixed sections were digested with trypsin 
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at 37°C for 20 minutes prior to the immunodetection. Collagen III was detect-
ed by incubating sections with anticollagen III (Southern Biotech) as described 
(47). Elastin was detected by antielastin antibody (Cedar Lane Labs), followed 
by secondary stages of immunostaining as previously described (7). TGF-β1 
was detected in formalin-fixed sections using anti-mouse TGF-β1 antibodies, 
followed by donkey anti-rabbit Cy3-conjugated secondary antibody (Jackson 
Laboratories). Immunolabeled sections were mounted in Vectorshield with 
DAPI. For detection of SAMs prior to in situ hybridization, tissue sections 
were incubated with rat anti-F4/80 (Abcam), followed by biotinylated anti-
rat antibodies and streptavidin-alkaline phosphatase (DAKO), and immu-
nodetection completed with Vector Red substrate (Vector Laboratories). All 
other liver sections were counterstained with hematoxylin, H&E, or picro-
sirius red as appropriate. To measure proliferation, mice were injected with 
BrdU (Boehringer Manheim) (50 μg/g) i.p. 2 hours prior to harvesting of liv-
ers. Sections were incubated with anti-BrdU (Serotec) as described (48). To 
assess apoptosis, TUNEL staining was performed using commercial products 
(Oncogene Research Products) as described (7, 49).
In situ hybridization technique
Following the immunodetection of F4/80, sections were incubated in 1 
M sodium thiocyanate for 10 minutes at 80°C, washed in PBS, and then 
digested in pepsin (0.4% wt/vol) in 0.1 M HCl at 37°C for 12 minutes. 
The protease was quenched in glycine (0.2% wt/vol) in 2× PBS, and then 
sections were rinsed in PBS, postfixed in paraformaldehyde (4% wt/vol) 
in PBS, dehydrated through graded alcohols, and air dried. FITC-labeled 
Y-chromosome paint (Star-FISH; Cambio) was used in the supplier’s 
hybridization mix, added to the sections, sealed under glass with rubber 
cement, heated to 80°C for 10 minutes and incubated overnight at 37°C. 
The slides were rinsed in 0.5× SSC and then in PBS. Slides were mounted 
in DAPI/Citifluor prior to fluorescent microscopy.
Assessment of tissue sections
Rat SAMs were scored as number per high-power field (hpf). An ED-1–posi-
tive cell was included if it was within or apposed to the scar. Rat α-SMA–
positive cells were counted as previously described (7). Mouse SAMs were 
assessed morphometrically using Fovea Pro 3.5 software (Reindeer Graph-
ics) to quantify the area of tissue occupied by positive staining (47). At least 
10 serial images were taken of the tissue section (×100), covering the whole 
tissue section. Collagen III immunostaining was assessed morphometrically 
for percentage area of liver occupied by collagen III matrix. Picrosirius red–
stained sections and α-SMA–stained sections were assessed morphometri-
cally by the same method. In addition, because computerized morphometry 
cannot distinguish fibrotic bands from perisinusoidal fibrosis, the latter 
was scored blindly by an established scoring system where +4 is established 
cirrhosis, +3 is advanced fibrosis, +2 is early bridging fibrosis, and +1 is early 
pericellular fibrotic changes (33). Due to the relatively low levels of elastin 
deposition, this was also scored using a similar blinded scoring method 
ranging from 0–4 (33). Whole tissue sections were assessed blindly for BrdU+ 
nuclei and TUNEL+ cells in scar tissue as previously described (7, 45, 48). To 
determine the origins of SAMs, F4/80-staining SAMs were considered to be 
of BM origin if the nucleus also contained a green fluorescent region due to 
the presence of Y-chromosomal DNA as previously described (34). Because 
not all SAMs in the section will exhibit the nucleus, tissue sections from 
male mice with the same disease were prepared in the same way and scored 
for the proportion of SAMs with nuclei containing Y-chromosomal DNA. 
Using this score (62.0%) as a maximum, the proportion of SAMs of male 
origin in the chimeras was calculated.
Real time RT-PCR
RNA was purified from diseased livers using the RNAeasy kit (Qiagen). In 
brief, tissue was homogenized in a buffer containing guanidine isothio-
cyanate and then passed over a silica-based gel that selectively binds RNA. 
Purified RNA was eluted following washing of the gel. Following DNase 
treatment, cDNA was generated from 1 ng of whole RNA using iScript 
cDNA synthesis kit (BioRad Laboratories), which relies on a combination 
oligo (dT) and random hexamers for annealing and an RNase H+ reverse 
transcriptase for accurate synthesis. cDNA was analyzed for content using 
a SYBR green–based, quantitative fluorescent PCR method (Qiagen). Fluo-
rescence was detected with the iCycler system (BioRad Laboratories). The 
following primer pairs were used for detection of specific cDNAs: GAPDH, 
5′-CTGAGAAACCTGCCAAGTA-3′, 5′-AAGAGTGGGAGTTGCTGTTG-3′; 
TNF-α, 5′-CGCTCTTCTGTCTACTGAACTT-3′, 5′-GATGAGAGGGAGGC-
CATT-3′; IL-10, 5′-CAGCCTTGCAGAAAAGAGAG-3′, 5′-GGAAGTGGGT-
GCAGTTATTG-3′; TGF-β, CTCCACCTGCAAGACCAT-3′, 5′-CTTAGTTT-
GGACAGGATCTGG-3′. Each assay was performed in duplicate a 25-μl 
reaction volume with 2× SYBR green mastermix, 1 μl of cDNA, and primers 
at 300 nM. The following PCR conditions were used: 95°C for 15 minutes, 
followed by 45 cycles of 94°C for 15 seconds, 50°C for 30 seconds, and 72°C 
for 30 seconds, followed by 72°C for a final 10 minutes. Each PCR reaction 
was also tested to assure a single product of the predicted size. Quantifica-
tion of each PCR product was expressed relative to GAPDH.
Statistics
Difference between percentage area measured morphometrically was 
expressed as mean ± SEM and assessed by ANOVA. Allotted scores were 
expressed as mean ± 95% confidence intervals and assessed using Wilcoxon 
ranked sum method.
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